Disease · MONDO_0005229
bacterial infectious disease with sepsis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bacterial infectious disease with sepsis. Diseases, record MONDO_0005229. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005229
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Bacteremia (disorder), Bacteremia NOS (disorder), Bacteremia, NOS, Unspecified bacteraemia, Unspecified bacteremia, Unspecified bacteremia (context-dependent category), bacteraemia, bacteremia, bacteriemia, symptomatic bacteremia
- Open Targets
- Highest stage of its drugs
- Approval, for 8 of its 32 drugs, from DailyMed, EMA Human Drugs and FDA
- Open Targets
Drugs32
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DAPTOMYCIN | CHEMBL387675 | Small molecule | Approval | EMA Human Drugs | 9 | 8 | 8 | Drugs and targets |
| MEROPENEM | CHEMBL127 | Small molecule | Approval | DailyMed and EMA Human Drugs | 4 | 2 | 2 | Drugs and targets |
| CEFTOBIPROLE MEDOCARIL SODIUM | CHEMBL4297101 | Small molecule | Approval | FDA | 2 | 1 | 1 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| VABORBACTAM | CHEMBL3317857 | Small molecule | Approval | EMA Human Drugs | 2 | 1 | 1 | Drugs and targets |
| CEFEPIME HYDROCHLORIDE | CHEMBL1200962 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PENICILLIN V | CHEMBL615 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| POLYMYXIN B SULFATE | CHEMBL5314355 | Protein | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| VANCOMYCIN | CHEMBL262777 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CEFAZOLIN | CHEMBL1435 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 32
See all 32 drugsTargets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03894046 | Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex | Phase 3 | 207 | 2023-02-01 | Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC | DURLOBACTAM, SULBACTAM | Its record names the disease | ClinicalTrials.gov |
| NCT04775953 | DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia | Phase 2 | 200 | 2024-10-22 | Staphylococcal Bacteraemia | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01967225 | Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections | Phase 3 | 125 | 2018-10-04 | Skin Diseases, Infectious | TEDIZOLID PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT02208063 | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial | Phase 3 | 121 | 2020-02-17 | Bacteremia | CEFAZOLIN, DAPTOMYCIN, PENICILLIN G POTASSIUM, TELAVANCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | Phase 2 | 100 | 2024-03-12 | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | IMIPENEM, RELEBACTAM | Its record names the disease | ClinicalTrials.gov |
| NCT01728376 | Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) | Phase 4 | 82 | 2016-12-07 | Bacteremia | DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02168946 | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Phase 3 | 77 | 2018-12-11 | Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection | MEROPENEM, VABORBACTAM | Its record names the disease | ClinicalTrials.gov |
| NCT03643952 | Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) | Phase 2 | 18 | 2021-03-30 | Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious | DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT06958835 | Linezolid Plus Standard of Care | Not applicable | 606 | Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) | LINEZOLID | Its record names the disease | ClinicalTrials.gov | |
| NCT03869437 | RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI | Phase 2 | 513 | Bloodstream Infections | CEFIDEROCOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dalbavancin vs Standard of Care: Frequency of All-Cause Mortality (A Component of DOOR) | 4 of 100 | 4 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of AEs Leading to Study Drug Discontinuation | 3 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Clinical Efficacy | 73 of 100 | 72 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of SAEs (A Component of DOOR) | 40 of 100 | 34 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of AEs Leading to Study Drug Discontinuation (A Component of DOOR) | 3 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Infectious Complications (A Component of DOOR) | 13 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: deaths from any cause | 5 of 100 | 4 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Clinical Failure (A Component of DOOR) | 20 of 100 | 22 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of SAEs | 43 of 100 | 37 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: serious adverse events | 43 of 100 | 37 of 100 | 200 | NCT04775953 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005229
GET https://conductscience.org/api/diseases/v1/MONDO_0005229/drugs?page=2